WALTHAM, Mass • 2024-02-06

BostonGene Demonstrates Benefits of Integrated Tumor Tissue and Blood Profiling at SLAS2024 International Conference and Exhibition

5 min to read

Revolutionizing immunotherapy prediction, BostonGene’s advanced profiling combines features of each patient’s tumor and immune system, paving the way for more effective treatments and improved clinical outcomes
WALTHAM, Mass, February 6, 2024 — BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will participate in and present at the SLAS2024 International Conference and Exhibition on February 3 – 7, 2024, in Boston, MA at the Boston Convention & Expo Center. This global event brings together a diverse community of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to transform research.

BostonGene session details are below:

Integrating molecular and immune profiling of tumor and blood for better immunotherapy response prediction

Tuesday, February 6, 2024 | 10:30 AM ET
Speaker: Nathan Fowler, MD, Chief Medical Officer, BostonGene
Location: 201C

Over the past decade, cancer treatment has been revolutionized by the emergence of immunotherapies. However, many patients experience low response rates and adverse effects, highlighting the need for better approaches to identify more accurate predictors of therapeutic response. To address this need, BostonGene combines molecular and immune profiling techniques to provide a comprehensive portrait of a cancer patient’s tumor and immune system. Using artificial intelligence and machine learning systems, BostonGene integrates data from CLIA-certified DNA and RNA sequencing, flow cytometry, and multiplex imaging to characterize the patient’s tumor and its microenvironment, which plays a role in cancer progression and treatment response. Further analysis of the distribution of cell populations in the peripheral blood is performed with a machine learning-based clinical immune profiling platform using multiparametric flow cytometry, providing an overview of a patient’s overall immune health and potential for response to immunotherapy. Integration of these technologies that analyze the tumor tissue and blood shows the potential for accurately predicting immunotherapy responses, ultimately providing patients with more effective treatments that lead to improved clinical outcomes.

To learn more or schedule a meeting with BostonGene during the event, please contact Maria Proia at maria.proia@bostongene.com.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin O’Reilly

Senior Director